federal_register: 2022-28404
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-28404 | Prospective Grant of an Exclusive Patent License: Development and Commercialization of Natural Killer Cell Therapies for Cancer | Notice | The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Replay Holdings LLC ("Replay") located in San Diego, California. | 2022-12-30 | 2022 | 12 | https://www.federalregister.gov/documents/2022/12/30/2022-28404/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-natural-killer | https://www.govinfo.gov/content/pkg/FR-2022-12-30/pdf/2022-28404.pdf | Health and Human Services Department; National Institutes of Health | 221,353 | The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent... |